Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00074698 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis
A Phase 1 study, sponsored by Kyntra Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT00074698 is a Phase 1 study that has completed, run by Kyntra Bio. The registered enrollment target is 21 participants.
The verdict
NCT00074698, a Phase 1 study, has completed, sponsored by Kyntra Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of FG-3019, a therapeutic antibody designed to block the pro-fibrotic activity of connective tissue growth factor (CTGF). CTGF triggers the production of collagen and fibronectin, which cause scarring and thickening of the lungs. Participants will be assigned sequentially to one of the 3 dose group: Low, medium, and high FG-3019.
Interventions
- DRUG FG-3019
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2003-12-08 |
| Est. Completion | 2004-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00074698
The ClinicalTrials.gov registry entry for NCT00074698 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyntra Bio, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FG-3019 is the first listed.
NCT00074698 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00074698 about?
NCT00074698 is a clinical study titled "Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis". The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of FG-3019, a therapeutic antibody designed to block the pro-fibrotic activity of connective tissue growth factor (CTGF). CTGF triggers the production of collagen and fibronectin, which cause...
What is the current status of trial NCT00074698?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2003-12-08. Estimated completion is 2004-05.
What interventions are being tested in trial NCT00074698?
The interventions under investigation include: FG-3019 (DRUG).
Who is sponsoring clinical trial NCT00074698?
This trial is sponsored by Kyntra Bio, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.